William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA,
Clinical Research and Project Management Office, The First Hospital of Lanzhou University, Lanzhou, China,
Cells Tissues Organs. 2022;211(4):368-384. doi: 10.1159/000508182. Epub 2020 Jul 2.
Millions of people worldwide with incurable liver disease die because of inadequate treatment options and limited availability of donor organs for liver transplantation. Regenerative medicine as an innovative approach to repairing and replacing cells, tissues, and organs is undergoing a major revolution due to the unprecedented need for organs for patients around the world. Induced pluripotent stem cells (iPSCs) have been widely studied in the field of liver regeneration and are considered to be the most promising candidate therapies. This review will conclude the current state of efforts to derive human iPSCs for potential use in the modeling and treatment of liver disease.
全球数以百万计患有不治之症的肝病患者因治疗选择不足和可供肝移植的供体器官有限而死亡。再生医学作为一种修复和替代细胞、组织和器官的创新方法，由于全球患者对器官的空前需求，正在经历一场重大革命。诱导多能干细胞（iPSC）在肝脏再生领域得到了广泛研究，被认为是最有前途的候选治疗方法。本综述将总结目前为潜在用于肝脏疾病建模和治疗而诱导人类 iPSC 的努力状况。
